AstraZeneca plans New York Stock Exchange listing but isn’t quitting London
FTSE 100’s second-biggest firm will also retain HQ in Cambridge and maintain its London listing
The drugmaker AstraZeneca is preparing to directly list its shares on the New York Stock Exchange, but said it will continue to be listed in London amid speculation over its future.
The FTSE 100 company said its direct listing in New York will replace trading in its “American depositary receipts” (ADRs) – which give US investors exposure to a non-US company – on the Nasdaq.